文献速递神经肿瘤

KMT2A是IDH突变胶质瘤恶性转化中的必要条件

KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究在条件性表达IDH1R132H的人星形胶质细胞模型中,通过抑制KMT2A干预H3K4me3沉积,发现KMT2A抑制可下调L1CAM表达及LGG相关基因程序,损害侵袭、迁移和增殖能力,但在原位TS603模型中敲低KMT2A反而缩短生存,提示阶段和情境依赖性效应。

要点

  • KMT2A介导的H3K4me3沉积对IDH1R132H驱动胶质瘤起始具有重要作用。
  • KMT2A抑制在体外削弱LGG相关表型,但原位模型生存结果相反。
  • 靶向KMT2A轴及其下游SCD需谨慎并考虑微环境因素。

核心结论

  • 破坏KMT2A介导的H3K4me3沉积可重塑表观基因组并在体外减弱LGG相关程序和表型,支持其在肿瘤起始中的重要作用。
  • 原位TS603模型中敲低KMT2A缩短生存,提示对肿瘤维持的效应具有情境依赖性。

研究设计与样本

  • 在条件性表达IDH1R132H的人星形胶质细胞模型中使用KMT2A抑制剂MM-102靶向H3K4me3并进行表型与组学分析。
  • 在患者来源IDH1R132H胶质瘤细胞系中使用shRNA介导的敲低进行验证。
  • 使用CUT&Tag和MethylationEPIC表征表观遗传改变,并使用siRNA评估下游靶点。

主要发现

  • KMT2A抑制显著降低L1CAM表达并导致广泛转录下调,包括LGG标志基因。
  • 转录组和蛋白质组分析提示脂质代谢和迁移能力改变。
  • 表型分析显示侵袭、迁移和增殖受损。
  • 在DEGs启动子处观察到H3K4me3沉积显著减少,并与部分CpG DNA甲基化增加相关。
  • 鉴定SCD为推定的KMT2A依赖性效应分子,其敲低降低克隆形成能力。

临床怎么用

  • KMT2A轴及其下游靶点如SCD作为治疗方向需谨慎探索并考虑肿瘤微环境。
  • 体外结果不能直接外推至体内维持阶段,需结合情境评估KMT2A靶向策略。

局限性

  • 原位TS603模型中KMT2A敲低缩短生存,与体外结果相反,提示结论受模型和阶段限制。
  • SCD仅为推定的KMT2A依赖性效应分子,尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IDH1R132H is the defining mutation of low-grade gliomas (LGGs), driving broad epigenetic rewiring that leads to malignant transformation. Recent studies have demonstrated that cell fate change from astrocyte to LGG is accompanied by redistribution of H3K4 methylation. By modulating the H3K4 methyltransferase KMT2A in a conditionally IDH1R132H-expressing human astrocyte model system, we sought to define requirements of IDH1R132H-dependent gliomagenesis and identify novel therapeutic targets. METHODS: Using the KMT2A inhibitor MM-102, we targeted H3K4me3 in IDH1R132H-expressing astrocytes and profiled L1CAM expression, proliferation, clonogenicity, invasion, migration, transcriptional and translational changes. Findings were validated in patient-derived IDH1R132H glioma lines using shRNA-mediated knockdown. Epigenetic transformation was characterized with CUT&Tag and MethylationEPIC, and downstream targets were assessed using siRNAs. RESULTS: KMT2A inhibition significantly decreased L1CAM expression and led to broad transcriptional downregulation, including that of LGG marker genes. Transcriptomic and proteomic analyses pointed to altered lipid metabolism and migratory capacity. Phenotypic characterization revealed impaired invasion, migration, and proliferation. We observed significantly reduced H3K4me3 deposition at the promoters of DEGs and increased DNA methylation at subsets of CpGs associated with H3K4me3 loss and downregulated genes. We identified SCD as a putative KMT2A-dependent effector whose knockdown reduced clonogenicity. In patient-derived models, KMT2A suppression impaired viability and spheroid growth in vitro; however, in an orthotopic TS603 model, knockdown shortened survival, indicating stage- and context-dependent effects. CONCLUSIONS: Disrupting KMT2A-mediated H3K4me3 deposition reshapes the epigenome and attenuates LGG-relevant programs and phenotypes in vitro, supporting a strong role in tumor initiation. In vivo, the survival results in the TS603 model highlight context-dependent effects on tumor maintenance and prompt cautious, microenvironment-aware therapeutic exploration of the KMT2A axis and its downstream targets, such as SCD.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Koch MS, Deo M, Schmidt C, et al. KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis. Neuro Oncol. 2026. PMID: 41537229. doi:10.1093/neuonc/noag006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。